Sasha Gusev: Thoughts on AI in academia. They are good ones. Extra points for leading me to an article from Sam Kriss in Harper’s Magazine about some magnificently agentic stupid people spending away their youth in San Francisco. Ruxandra Teslo: Manufacturing requirements are killing cell and gene therapy. The FDA wants companies to make at least two batches of product at the highest standard of manufacturing before approving it for commercial use. You should know this before starting your clinical program, especially if you have manufacturing that’s expensive, so maybe make two small batches instead of a big one? Just a thought. Separately, none of this would be an issue if there was momentum towards considering cell & gene therapy more of a blood bank/cell processing thing than a commercial drug. But then you couldn’t charge as much, could you? Regan Penaluna for Nautilus: Lessons in Chemistry, 19th-Century Style. Frustratingly, it takes Penaluna four paragraphs to mention the full…
No comments yet. Log in to reply on the Fediverse. Comments will appear here.